Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,400 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 5 February 2020) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download: 

(PDF, 3MB, 197 pages)

 

Export 115 results:
Author Title [ Type(Desc)] Year
Filters: Author is van Staa, T. P.  [Clear All Filters]
Journal Article
T. P. van Staa, Card, T., Logan, R. F., and Leufkens, H. G., “5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study”, Gut, vol. 54, pp. 1573-8, 2005.
T. P. van Staa, Travis, S., Leufkens, H. G., and Logan, R. F., “5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study”, Gastroenterology, vol. 126, pp. 1733-9, 2004.
V. Abbing-Karahagopian, Huerta, C., Souverein, P. C., de Abajo, F., Leufkens, H. G., Slattery, J., Alvarez, Y., Miret, M., Gil, M., Oliva, B., Hesse, U., Requena, G., de Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlienger, R. G., de Groot, M. C., Klungel, O. H., van Staa, T. P., van Dijk, L., Egberts, A. C., Gardarsdottir, H., and De Bruin, M. L., “Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications”, Eur J Clin Pharmacol, vol. 70, pp. 849-57, 2014.
C. Klop, Gibson-Smith, D., Elders, P. J., Welsing, P. M., Leufkens, H. G., Harvey, N. C., Bijlsma, J. W., van Staa, T. P., and de Vries, F., “Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010”, Osteoporos Int, vol. 26, pp. 1919-28, 2015.
T. P. van Staa, Bishop, N., Leufkens, H. G., and Cooper, C., “Are inhaled corticosteroids associated with an increased risk of fracture in children?”, Osteoporos Int, vol. 15, pp. 785-91, 2004.
S. R. Pye, Sheppard, T., Joseph, R. M., Lunt, M., Girard, N., Haas, J. S., Bates, D. W., Buckeridge, D. L., van Staa, T. P., Tamblyn, R., and Dixon, W. G., “Assumptions made when preparing drug exposure data for analysis have an impact on results: An unreported step in pharmacoepidemiology studies”, Pharmacoepidemiol Drug Saf, vol. 27, pp. 781-788, 2018.
V. Abbing-Karahagopian, Kurz, X., de Vries, F., van Staa, T. P., Alvarez, Y., Hesse, U., Hasford, J., Dijk, L., de Abajo, F. J., Weil, J. G., Grimaldi-Bensouda, L., Egberts, A. C., Reynolds, R. F., and Klungel, O. H., “Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project”, Curr Clin Pharmacol, vol. 9, pp. 130-8, 2014.
R. Boggon, van Staa, T. P., Chapman, M., Gallagher, A. M., Hammad, T. A., and Richards, M. A., “Cancer recording and mortality in the General Practice Research Database and linked cancer registries”, Pharmacoepidemiol Drug Saf, vol. 22, pp. 168-75, 2013.
R. Williams, van Staa, T. P., Gallagher, A. M., Hammad, T., Leufkens, H. G. M., and de Vries, F., “Cancer recording in patients with and without type 2 diabetes in the Clinical Practice Research Datalink primary care data and linked hospital admission data: a cohort study”, BMJ Open, vol. 8, p. e020827, 2018.
A. Lalmohamed, Bazelier, M. T., van Staa, T. P., Uitdehaag, B. M., Leufkens, H. G., de Boer, A., and de Vries, F., “Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study”, Eur J Neurol, vol. 19, pp. 1007-14, 2012.
E. Setakis, Leufkens, H. G., and van Staa, T. P., “Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib”, Arthritis Rheum, vol. 59, pp. 1105-11, 2008.
C. J. Edwards, Arden, N. K., Fisher, D., Saperia, J. C., Reading, I., van Staa, T. P., and Cooper, C., “The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database”, Rheumatology (Oxford), vol. 44, pp. 1394-8, 2005.
T. P. van Staa, Cooper, C., Leufkens, H. G., and Bishop, N., “Children and the risk of fractures caused by oral corticosteroids”, J Bone Miner Res, vol. 18, pp. 913-8, 2003.
T. P. van Staa, Geusens, P., Bijlsma, J. W., Leufkens, H. G., and Cooper, C., “Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis”, Arthritis Rheum, vol. 54, pp. 3104-12, 2006.
R. Boggon, van Staa, T. P., Timmis, A., Hemingway, H., Ray, K. K., Begg, A., Emmas, C., and Fox, K. A., “Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction–a hospital registry-primary care linked cohort (MINAP-GPRD)”, Eur Heart J, vol. 32, pp. 2376-86, 2011.
M. C. Gulliford, van Staa, T. P., McDermott, L., McCann, G., Charlton, J., and Dregan, A., “Cluster randomized trials utilizing primary care electronic health records: methodological issues in design, conduct, and analysis (eCRT Study)”, Trials, vol. 15, p. 220, 2014.
H. A. van den Ham, Klungel, O. H., Singer, D. E., Leufkens, H. G., and van Staa, T. P., “Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database”, J Am Coll Cardiol, vol. 66, pp. 1851-9, 2015.
T. P. van Staa, Leufkens, H. G., Zhang, B., and Smeeth, L., “A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example”, PLoS Med, vol. 6, p. e1000194, 2009.
T. P. van Staa, Setakis, E., Di Tanna, G. L., Lane, D. A., and Lip, G. Y., “A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice”, J Thromb Haemost, vol. 9, pp. 39-48, 2011.
F. de Vries, Setakis, E., and van Staa, T. P., “Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes”, Br J Clin Pharmacol, vol. 70, pp. 429-38, 2010.
K. Wing, Douglas, I., Bhaskaran, K., Klungel, O. H., Reynolds, R. F., Pirmohamed, M., Smeeth, L., and van Staa, T. P., “Development of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records”, Drug Discov Today, vol. 19, pp. 361-6, 2014.
S. Venkatesan, Myles, P. R., McCann, G., Kousoulis, A. A., Hashmi, M., Belatri, R., Boyle, E., Barcroft, A., van Staa, T. P., Kirkham, J. J., Van Tam, J. S. Nguyen, Williams, T. J., and Semple, M. G., “Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study”, Health Technol Assess, vol. 19, pp. 1-132, 2015.
Y. Li, Sperrin, M., Belmonte, M., Pate, A., Ashcroft, D. M., and van Staa, T. P., “Do population-level risk prediction models that use routinely collected health data reliably predict individual risks?”, Sci Rep, vol. 9, p. 11222, 2019.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Does a fracture at one site predict later fractures at other sites? A British cohort study”, Osteoporos Int, vol. 13, pp. 624-9, 2002.
T. P. van Staa, Rietbrock, S., Setakis, E., and Leufkens, H. G., “Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?”, J Intern Med, vol. 264, pp. 481-92, 2008.
A. Thompson, Ashcroft, D. M., Owens, L., van Staa, T. P., and Pirmohamed, M., “Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study”, PLoS One, vol. 12, p. e0173272, 2017.
T. P. van Staa, Smeeth, L., Ng, E. S., Goldacre, B., and Gulliford, M., “The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?”, Heart, vol. 99, pp. 1597-602, 2013.
I. E. Bultink, Harvey, N. C., Lalmohamed, A., Cooper, C., Lems, W. F., van Staa, T. P., and de Vries, F., “Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom”, Osteoporos Int, vol. 25, pp. 1275-83, 2014.
A. Thompson, Wright, A. K., Ashcroft, D. M., van Staa, T. P., and Pirmohamed, M., “Epidemiology of alcohol dependence in UK primary care: Results from a large observational study using the Clinical Practice Research Datalink”, PLoS One, vol. 12, p. e0174818, 2017.
C. Cooper, Dennison, E. M., Leufkens, H. G., Bishop, N., and van Staa, T. P., “Epidemiology of childhood fractures in Britain: a study using the general practice research database”, J Bone Miner Res, vol. 19, pp. 1976-81, 2004.
T. P. van Staa, Dennison, E. M., Leufkens, H. G., and Cooper, C., “Epidemiology of fractures in England and Wales”, Bone, vol. 29, pp. 517-22, 2001.
E. M. Curtis, van der Velde, R., Moon, R. J., van den Bergh, J. P., Geusens, P., de Vries, F., van Staa, T. P., Cooper, C., and Harvey, N. C., “Epidemiology of fractures in the United Kingdom 1988-2012: Variation with age, sex, geography, ethnicity and socioeconomic status”, Bone, vol. 87, pp. 19-26, 2016.
C. Klop, van Staa, T. P., Cooper, C., Harvey, N. C., and de Vries, F., “The epidemiology of mortality after fracture in England: variation by age, sex, time, geographic location, and ethnicity”, Osteoporos Int, vol. 28, pp. 161-168, 2017.
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., “Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?”, Pharmacoepidemiol Drug Saf, vol. 17, pp. 475-84, 2008.
R. M. Joseph, van Staa, T. P., Lunt, M., Abrahamowicz, M., and Dixon, W. G., “Exposure measurement error when assessing current glucocorticoid use using UK primary care electronic prescription data”, Pharmacoepidemiol Drug Saf, 2018.
R. M. Joseph, van Staa, T. P., Lunt, M., Abrahamowicz, M., and Dixon, W. G., “Exposure measurement error when assessing current glucocorticoid use using UK primary care electronic prescription data”, Pharmacoepidemiol Drug Saf, vol. 28, pp. 179-186, 2019.
A. M. Gallagher, Rietbrock, S., Olson, M., and van Staa, T. P., “Fracture outcomes related to persistence and compliance with oral bisphosphonates”, J Bone Miner Res, vol. 23, pp. 1569-75, 2008.
F. de Vries, Cooper, A. L., Cockle, S. M., van Staa, T. P., and Cooper, C., “Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates”, Osteoporos Int, vol. 20, pp. 1989-98, 2009.
F. de Vries, Bracke, M., Leufkens, H. G., Lammers, J. W., Cooper, C., and van Staa, T. P., “Fracture risk with intermittent high-dose oral glucocorticoid therapy”, Arthritis Rheum, vol. 56, pp. 208-14, 2007.
T. P. van Staa, Patel, D., Gallagher, A. M., and De Bruin, M. L., “Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data”, Diabetologia, vol. 55, pp. 654-65, 2012.
S. Rietbrock, Plumb, J. M., Gallagher, A. M., and van Staa, T. P., “How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database”, Thromb Haemost, vol. 101, pp. 527-34, 2009.
J. T. Nielen, van den Bemt, B. J., Boonen, A., Dagnelie, P. C., Emans, P. J., Veldhorst, N., Lalmohamed, A., van Staa, T. P., and de Vries, F., “Identification of antithrombotic drugs related to total joint replacement using anonymised free-text notes: a search strategy in the Clinical Practice Research Datalink”, BMJ Open, vol. 5, p. e009017, 2015.
C. J. Edwards, Cooper, C., Fisher, D., Field, M., van Staa, T. P., and Arden, N. K., “The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis”, Arthritis Rheum, vol. 57, pp. 1151-7, 2007.
T. P. van Staa, Selby, P., Leufkens, H. G., Lyles, K., Sprafka, J. M., and Cooper, C., “Incidence and natural history of Paget's disease of bone in England and Wales”, J Bone Miner Res, vol. 17, pp. 465-71, 2002.
P. C. Souverein, Webb, D. J., Petri, H., Weil, J., van Staa, T. P., and Egberts, T., “Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database”, Epilepsia, vol. 46, pp. 304-10, 2005.
T. P. van Staa, Geusens, P., Zhang, B., Leufkens, H. G., Boonen, A., and Cooper, C., “Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids”, Rheumatology (Oxford), vol. 46, pp. 460-6, 2007.
T. P. van Staa, Cooper, C., Barlow, D., and Leufkens, H. G., “Individualizing the risks and benefits of postmenopausal hormone therapy”, Menopause, vol. 15, pp. 374-81, 2008.
A. M. Gallagher, Rietbrock, S., Plumb, J., and van Staa, T. P., “Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?”, J Thromb Haemost, vol. 6, pp. 1500-6, 2008.
P. J. Peeters, Bazelier, M. T., Leufkens, H. G., Auvinen, A., van Staa, T. P., de Vries, F., and De Bruin, M. L., “Insulin glargine use and breast cancer risk: Associations with cumulative exposure”, Acta Oncol, vol. 55, pp. 851-8, 2016.
D. E. Robinson, van Staa, T. P., Dennison, E. M., Cooper, C., and Dixon, W. G., “The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: A cohort study”, Bone, vol. 117, pp. 83-90, 2018.
[Page last reviewed 5 February 2020]